Head-to-head evidence
Furosemide (subcutaneous, scPharmaceuticals) vs Furosemide (subcutaneous, SQ Innovation)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: NKCC2 · full Heart Failure pipeline
Furosemide (subcutaneous, scPharmaceuticals) · FUROSCIX
Marketed by scPharmaceuticals and partners
NCT03458325 · Phase 3 · completed
This was a small, open-label, nonrandomized single-group study: 25 participants received Furoscix, with comparison made against propensity-matched historical claims controls rather than a concurrently randomized control group. The primary endpoint was 30-day healthcare utilization cost, a surrogate economic measure, and the reported comparison favored Furoscix with p<0.0001, but the limited design and sample size reduce confidence in the finding.
Next expected readout: November 2026 · NCT07008365 (registry estimate)
Furosemide (subcutaneous, SQ Innovation) · Lasix ONYU
Marketed by SQ Innovation
NCT02579057 · Phase 2/3 · completed
Patients were randomized to subcutaneous or intravenous furosemide, but the study was open-label with no blinding, and no formal statistical comparison of urine output between the two routes was reported, so this is limited evidence rather than a clear efficacy demonstration.
Next expected readout: November 2026 · NCT07008365 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Furosemide (subcutaneous, scPharmaceuticals)'s landscape · Furosemide (subcutaneous, SQ Innovation)'s landscape